Cologuard Plus™ test

The Cologuard Plus test is approved for average-risk patients 45 and older1 and is backed by pivotal data from the 20,000+-person BLUE-C study published in the New England Journal of Medicine.

Built on the proven performance of the Cologuard® test, the Cologuard Plus test detects 95% of colorectal cancer (CRC) at 94% specificity in the U.S. screening population.1*  It also detects 74% of high-grade dysplasia, the type of pre-cancerous growths most likely to advance to cancer.† With its enhanced specificity, the Cologuard Plus test is expected to reduce unnecessary follow-up colonoscopies by up to 40% compared to the original Cologuard test. This performance makes the Cologuard Plus test the most accurate noninvasive CRC test reported in studies to date.†

Like the original Cologuard test, the Cologuard Plus test maintains the convenience of at-home collection with no prep, diet restrictions, or sedation. It is shipped directly to a patient’s home and integrates with Exact Sciences’ technology platform, ExactNexus™, which simplifies ordering, result delivery, and patient navigation.

A lab technician processing a Cologuard sample.

Footnotes and references

  1. 94% specificity was determined for adults with no colorectal neoplasia age-weighted to the U.S. population.
  2. Based on relative comparison to published reports; not direct evidence from head-to-head comparisons with all other screening tests.

  1. Cologuard Plus Clinician Brochure. Madison, WI; Exact Sciences Corporation.